

Studientitel	PRAEGNANT: Prospektives akademisches translationales Forschungsnetzwerk zur Optimierung der onkologischen Versorgungsqualität in der adjuvanten und fortgeschrittenen/metastasierten Situation, Versorgungsforschung, Pharmakogenetik, Biomarker und Pharmaökonomie	
ClinicalTrials.gov Identifier	NCT02338167	
Sponsor	Universitätsklinikum Tübingen	
Ansprechpartner*in	Prof. Dr. Diana Lüftner	
Kontakt Studienzentrale	An- schrift	Charité - Universitätsmedizin Berlin Campus Benjamin Franklin Hindenburgdamm 30, 12203 Berlin
	Tel.	+49 30 450 513 524
Kontakt Cancer-Hotline	+49 30 450 564 222 Email: ccc@charite.de	
Wichtigste Einschlusskriterien	<p>Inclusion Criteria for the early breast cancer setting:</p> <ul style="list-style-type: none"> • Adult breast cancer patients (age ≥ 18 years) • Patients with breast cancer and no evidence of distant metastases with a diagnosis not longer than 91 days before study entry • Patients, who are able and willing to sign the informed consent form <p>Inclusion Criteria for the advanced/metastatic setting:</p> <ul style="list-style-type: none"> • Adult women aged ≥ 18 years • Patients with the diagnosis of invasive breast cancer (in German: Mammakarzinom, as opposed to "non-invasive"= ductales Carcinoma in situ; irrespective of status of BC, e.g. TNM, re-ceptor status etc.) and • Patients, who are willing and able to sign the informed consent form • Patients with metastatic or locally advanced, inoperable disease proven by clinical measures (i.e. standard imaging) 	